Like a Mouse Cornered By A Cat, Allergan Fights The FutureMark Melin
As Allergan, Inc. (NYSE:AGN) squirms like a mouse trapped in a corner by a cat, trying desperately to stave off an acquisition by slash and burn roll-up firm Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX), a letter from a decade long institutional investor points to apparent inconsistencies in management tactics.
Allergan claims Valeant's acquisition offers undervalue the company
Allergan, Inc. (NYSE:AGN)’s board is currently claiming that acquisition offer by Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) (and potentially a
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.